Displaying drugs 1001 - 1025 of 1286 in total
AT-7519
AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.
Investigational
Matched Description: … AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression …
ATL1102
ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
Investigational
Matched Description: … ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, …
Tandamine
Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).
Experimental
Matched Description: … Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI). …
Navtemadlin
Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia).
Investigational
Matched Description: … Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and …
Mitiperstat
Mitiperstat is under investigation in clinical trial NCT05492877 (An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.).
Investigational
Matched Description: … investigation in clinical trial NCT05492877 (An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor …
Dubermatinib
Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).
Investigational
Matched Description: … Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor …
Paliroden
Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature neurons. It is indicated for use in Alzheimer's Disease and Parkinson’s.
Investigational
AVI-4065
AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency.
Investigational
AZD-9684
AZD-9684 is the first member of a new anti-thrombotic class (CPU inhibitors). It is being developed by AstraZeneca.
Investigational
AEG35156
A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome...
Investigational
Matched Description: … , a pivotal inhibitor of apoptosis that is overexpressed in many tumors. ... AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP) …
Stannsoporfin
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Investigational
Matched Description: … Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary …
Toloxatone
Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .
Experimental
Matched Description: … It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388]. …
RDEA806
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Investigational
Matched Description: … RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier …
Ethoxzolamide
Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. Its pharmacological activity thus confers the risk for hypokalemia.
Withdrawn
PA-1050040
PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Investigational
Matched Description: … PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). …
Talopram
Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.
Experimental
Matched Description: … Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram …
MRK-003
MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development.
Investigational
Matched Description: … MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. …
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
9,10-Deepithio-9,10-Didehydroacanthifolicin
A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)
Experimental
Matched Description: … A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. …
L-erythro-7,8-dihydrobiopterin
7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Experimental
Matched Description: … 7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes …
Larazotide
An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.
Investigational
Matched Description: … An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula …
Axatilimab
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Investigational
Matched Description: … Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor …
ASP-8731
ASP-8731 is a novel BACH1 inhibitor that potentially induces fetal hemoglobin (HbF). Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.
Investigational
Matched Description: … ASP-8731 is a novel BACH1 inhibitor that potentially induces fetal hemoglobin (HbF). …
Camostat
Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor.[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the...
Experimental
Matched Description: … Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor. …
ABT-341
ABT-341 is a potent and selective DPP-4 inhibitor with a structure very similar to sitagliptin (in 2D; the 3D structure is significantly different).
Experimental
Matched Description: … ABT-341 is a potent and selective DPP-4 inhibitor with a structure very similar to sitagliptin (in 2D …
Displaying drugs 1001 - 1025 of 1286 in total